News > RMMS Defeats Motion for Temporary Restraining Order and Preliminary Injunction Involving Generic Ramipril Capsules

RMMS Defeats Motion for Temporary Restraining Order and Preliminary Injunction Involving Generic Ramipril Capsules

06/10/2008

On June 10, 2008, the U.S. District Court for the District of Maryland denied a motion for temporary restraining order and preliminary injunction against the firm's clients, Lupin Limited and Lupin Pharmaceuticals, Inc. Plaintiffs King Pharmaceuticals, Inc. and King Pharmaceuticals Research and Development, Inc. filed their motion in order to prevent Lupin from bringing its FDA-approved generic version of Altace® (ramipril) capsules to the market pending resolution of the underlying patent infringement litigation. After considering the briefing and hearing oral argument from the parties, the Court ruled from the bench, finding that Plaintiffs had not established a likelihood of success on the merits, and denied Plaintiffs' motion.

This victory enabled Lupin to immediately launch its products and be among the first generic companies to offer generic ramipril capsules, 1.25 mg, 2.5 mg, 5 mg and 10 mg. This ruling follows the firm's successful challenge to another patent asserted against Lupin by King, which first opened the ramipril market to generic competition in 2007.